Inventor · disambiguated record
Paul Kirschmeier
Also filed as: KIRSCHMEIER PAUL · KIRSCHMEIER PAUL T
1 granted patent·9 pending applications·11 citations·filing 2004–2018
33Inventor score
Files withSCHERING CORP4ANTOCHSHUK VALENTYN1ARBUCK SUSAN1DANA FARBER CANCER INST INC1GUZI TIMOTHY J1
Top patents by PatentIndex Score
10 records- 0185US8673924B2Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitorsGUZI TIMOTHY J·Filed 2007·Granted Mar 18, 2014·11 cites·25 claims
- 0268US2009247599A1Methods of treating cell proliferative disorders using a compressed temozolomide dosing scheduleSCHERING CORP·Filed 2009·Application pending·0 cites
- 0351US2008090242A1Panel of biomarkers for prediction of fti efficacySCHERING CORP·Filed 2007·Application pending·0 cites
- 0448US2005119188A1Method of treating breast cancerFiled 2004·Application pending·0 cites
- 0547US2007111979A1Methods of treating cell proliferative disorders using a compressed temozolomide dosing scheduleROBERT BISHOP WALTER·Filed 2006·Application pending·0 cites
- 0646US2010104661A1Discontinuous methods of treating cancerARBUCK SUSAN·Filed 2007·Application pending·0 cites
- 0742US2006205810A1Platinum therapeutic combinationsSCHERING CORP·Filed 2005·Application pending·0 cites
- 0842US2010240723A1Methods of treating cell proliferative disorders using a compressed temozolomide dosing scheduleSCHERING CORP·Filed 2010·Application pending·0 cites
- 0940US2021382037A1Identification and use of cytotoxic t lymphocyte (ctl) antigen-specific target cell killing enhancer agentsDANA FARBER CANCER INST INC·Filed 2018·Application pending·0 cites
- 1036US2010286038A1Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the sameANTOCHSHUK VALENTYN·Filed 2008·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Paul Kirschmeier files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →